Hypera S.A. / Takeda Pharmaceutical Company Ltd.

Latin America OTC & Prescription Pharmaceuticals (Multi-Therapeutic Branded Portfolio Divestiture)

$75.0B Latin America pharmaceutical market 2020 · $825M Total transaction value (asset purchase, all-cash)

Disease Overview

The Hypera-Takeda transaction is a $825M asset purchase covering a portfolio of select OTC (over-the-counter) and prescription branded products across seven Latin American markets: Brazil, Mexico, Argentina, Colombia, Ecuador, Panama, and Peru. The portfolio is multi-therapeutic, spanning gastroenterology (Nesina, Trelagliptin), CNS (Reagila/cariprazine in select markets), respiratory, vitamin and supplement OTC franchises, and select branded primary-care assets. Latin America represents approximately 4-5% of the global pharmaceutical market by value, with Brazil as the largest single market (~$30B annually) and a growth profile of 6-8% CAGR driven by population aging, expanding private health insurance, and Brazil's Sistema Unico de Saude (SUS) public coverage. Hypera Pharma is the largest Brazilian-headquartered pharmaceutical company by branded prescription and OTC sales, focused on consumer healthcare and branded generics. The transaction is part of Takeda's $10B+ non-core asset divestiture program announced after its 2019 $62B acquisition of Shire, intended to reduce leverage from 4.7x net debt-to-EBITDA at deal close toward 2.0x by FY24. Takeda's Latin America revenue at deal signing was approximately $1B+, with the divested portfolio representing roughly 30-40% of regional revenue.

Competitive Landscape

The Latin America branded pharmaceutical competitive landscape is dominated by global multinationals (Pfizer, Sanofi, Bayer, Roche, Novartis, GSK, AstraZeneca) plus regional and Brazilian-headquartered specialty pharma. Brazilian competitors to Hypera include EMS Pharma (largest Brazilian generics by volume), Aché Laboratórios, Eurofarma, Novamed/Cristália, and Biolab Sanus. Takeda's divestiture moves into Hypera follow a regional pattern of multinational asset shedding into local consolidators: Sanofi divested portions of its primary-care portfolio to Cipla and Eurofarma; Bayer divested branded primary care to Eurofarma in 2020; Pfizer-Mylan combined into Viatris with significant Latin America rationalization; and Novartis spun out Sandoz with continued LatAm OTC focus. The Hypera transaction therefore represents both a Takeda deleveraging milestone and a market consolidation step for Hypera, which followed up with additional asset purchases including Brainfarma deals, building toward leadership in the branded prescription and OTC categories. Therapeutically, Mounjaro (tirzepatide), Trulicity (dulaglutide) from Lilly and Ozempic (semaglutide) from Novo dominate the diabetes category that overlaps Takeda's Nesina franchise; Vyvanse competes with Takeda's CNS positioning.